医学临床研究
   Jun. 18, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2022, Vol. 39 Issue (3): 439-441    DOI: 10.3969/j.issn.1671-7171.2022.03.033
Original Articles Current Issue | Archive | Adv Search |
Clinical Efficacy of Different Doses Febuxostat in the Treatment of Uric Acid End-stage Nephropathy
YIN Jun, QIU Jun-si, SHAO Fang
Department of Nephrology, Wuxi Second People's Hospital, Wuxi Jiangsu 214000, China
Download: PDF (1114 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】To investigate the clinical effects of febuxostat at different doses in the treatment of uric acid end-stage nephropathy (UAESN). 【Methods】A total of 98 UAESN patients treated in our hospital were selected and randomly divided into the observation group (n=49) and the control group (n=49).On the basis of conventional treatment, the observation group was given 20 mg febuxostat, and the control group was given 40mg febuxostat. Serum creatinine (SCr), glomerular filtration rate (eGFR), urinary microalbumin to creatinine ratio (ACR) and serum uric acid (SUA) were observed before and after treatment. Plasma viscosity (PV), whole blood low shear viscosity (ηL), whole blood high shear viscosity (ηH), malondialdehyde (MDA), advanced oxide protein product (AOPP), superoxide dismutase (SOD) and other oxidative stress indicators were recorded. The efficacy and adverse reactions of the two groups were compared. 【Results】Compared with before treatment, SCr and ACR were decreased, eGFR and SOD were increased, SUA, PV, ηL, ηH, MDA and AOPP were decreased after treatment (P<0.05). After treatment, there were no significant differences in SCr, ACR, eGFR, SUA, PV, ηL, ηH, MDA, AOPP and SOD between the two groups (P>0.05). There was no significant difference between the clinical efficacy of the observation group (91.84%) and the control group (95.92%) (P>0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05). 【Conclusion】Based on conventional treatment, 20 mg febuxostat has the same effect as 40 mg febuxostat in aspect of improving renal function, hemorheology, relieving oxidative stress and clinical efficacy of UAESN, however, 20 mg febuxostat has better safety.
Key wordsKidney Diseases/CO      Hyperuricemia/CO      Hyperuricemia/DT      Gout Suppressants/RU     
Received: 04 December 2021     
PACS:  R692  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
YIN Jun
QIU Jun-si
SHAO Fang
Cite this article:   
YIN Jun,QIU Jun-si,SHAO Fang. Clinical Efficacy of Different Doses Febuxostat in the Treatment of Uric Acid End-stage Nephropathy[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(3): 439-441.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.03.033     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I3/439
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech